Phase I Study of Safety and Efficacy of Allogeneic Natural Killer Cell Therapy in Relapsed/Refractory Neuroblastomas Post Autologous Hematopoietic Stem Cell Transplantation Publisher Pubmed

Summary: NK cells post-auto-HSCT safe in relapsed neuroblastoma; one long CR; more dosing explored. #Neuroblastoma #NKtherapy

Mohseni R¹ ; Mahdavi Sharif P¹ ; Behfar M¹ ; Shojaei S³ ; Shoaehassani A⁴ ; Jafari L¹ ; Khosravi A¹ ; Nikfetrat Z¹ ; Hamidieh AA¹
Source: Scientific Reports Published:2024

Abstract

Despite low incidence, neuroblastoma, an immunologically cold tumor, is the most common extracranial solid neoplasm in pediatrics. In relapsed/refractory cases, the benefits of autologous hematopoietic stem cell transplantation (auto-HSCT) and other therapies are limited. Natural killer (NK) cells apply cytotoxicity against tumor cells independently of antigen-presenting cells and the adaptive immune system. The primary endpoint of this trial was to assess the safety of the injection of allogenic, ex vivo-expanded and primed NK cells in relapsed/refractory neuroblastoma patients after auto-HSCT. The secondary endpoint included the efficacy of this intervention in controlling tumors. NK cells were isolated and primed ex vivo (by adding interleukin [IL]-2, IL-15, and IL-21) in a GMP-compliant CliniMACS system and administered to four patients with relapsed/refractory MYCN-positive neuroblastoma. NK cell injections (1 and 5 × 107 cells/kg in the first and second injections, respectively) were safe, and no acute or sub-acute adverse events were observed. During the follow-up period, one complete response (CR) and one partial response (PR) were observed, while two cases exhibited progressive disease (PD). In follow-up evaluations, two died due to disease progression, including the case with a PR. The patient with CR had regular growth at the 31-month follow-up, and another patient with PD is still alive and receiving chemotherapies 20 months after therapy. This therapy is an appealing and feasible approach for managing refractory neuroblastomas post-HSCT. Further studies are needed to explore its efficacy with higher doses and more frequent administrations for high-risk neuroblastomas and other immunologically cold tumors. Trial registration number: irct.behdasht.gov.ir (Iranian Registry of Clinical Trials, No. IRCT20201202049568N1). © The Author(s) 2024.